MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID
The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine. Moderna expects doses to reach select U.S. retailers in the coming weeks for the 2026-2027 season. After the COVID-19 pandemic propelled Moderna’s vaccine sales to a peak of more than $18 billion in 2022, demand collapsed, driving annual revenue down. … Read more